CD274 and neoplasm: The tumor mutation burden (TMB) or peripheral blood mononuclear cells (PBMC) have been found useful for prediction of response to ICIs [5, 6]; however, except for PD-L1 expression by immunohistochemistry, biomarkers with better prognostic efficacy remain to be established.